Newsfeeds Archive - Spark Newswire

2 minute read

Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More

June 18, 12:48 AM

As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics industries.Cybin Inc.announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. In addition, six cannabis companies announced changes to their respective boards of directors.

CSE:PLTH

5 minute read

‘Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching’ – Marijuana Moment

By Benzinga Newsdesk

June 12, 2:07 PM

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be

CMPS

2 minute read

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

By Aaron Bry

June 5, 3:26 PM

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

ATAI

2 minute read

Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon

By Nina Zdinjak

May 9, 9:29 AM

Florida-based cannabis companyÂ Kaya Holdings IncÂ ., AKA KAYS, (OTCQB:KAYS)Â has been awarded a license by the Oregon Health Authority to…

ATAI

2 minute read

“FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month” – Marijuana Moment

By Benzinga Newsdesk

May 7, 11:54 AM

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy

CMPS

4 minute read

Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024

By Benzinga Newsdesk

May 6, 8:42 AM

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -- Received U.S. Food and Drug

CYBN

3 minute read

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

By Lara Goldstein

March 30, 8:57 AM

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two…

CMND

3 minute read

Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss

By The Dales Report

February 16, 3:07 PM

The TDR Three Key Takeaways:

CYBN

3 minute read

Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs And More

By Lara Goldstein

February 15, 11:55 AM

Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items concerning the last few…

ATAI

3 minute read

‘FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says’ – Marijuana Moment

By Benzinga Newsdesk

February 12, 12:38 PM

https://www.marijuanamoment.net/fda-grants-priority-review-of-mdma-assisted-therapy-for-ptsd-psychedelics-drug-development-company-says/ The Food and Drug Administration (FDA) has agreed to review

CMPS